Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles

Atherosclerosis

Volumn 152, Issue 2, 2000, Pages 433-440

  Adlouni, Ahmed ^a   El Messal, Mariame ^b   Saïle, Rachid ^a   Parra, Henri Joseph ^c   Fruchart, Jean Charles ^c   Ghalim, Noredine ^d  

^a FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

^b FACULTÉ DES SCIENCES AIN CHOCK   (Morocco)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Institut Pasteur du Maroc   (Morocco)

Author keywords

CETP activity; Cholesterol efflux; Familial hypercholesterolemia; LCAT activity; Lipoprotein particle composition; Probucol

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROBUCOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; PRIORITY JOURNAL;

ADIPOCYTES; ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; GLYCOPROTEINS; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROBUCOL;

EID: 0033811696     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00493-1     Document Type: Article

References (47)

1. Miller G.J., Miller N.E. Plasma high-density lipoprotein concentration and development of ischemic heart disease. Lancet. i:1975;16-19.
2. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as protective factor against coronary heart disease: the Framingham study. Am. J. Med. 62:1977;707-714.
3. Barkia A., Puchois P., Ghalim N., Torpier G., Barbaras R., Ailhaud G., Fruchart J.C. Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells. Atherosclerosis. 87:1991;135-146.
4. Barter P. High-density lipoprotein and reverse cholesterol transport. Curr. Opin. Lipidol. 4:1993;210-217.
5. Barnhart J.W., Sefranka J.A., Mc Intosh D.D. Hypocholesterolemic effect of 4,4′-(isopropylidenedithio) bis(2,6-di-t-bytylphenol) (Probucol). Am. J. Clin. Nutr. 23:1970;1229-1233.
6. Zimetbaum P., Eder H., Frishman W.J. Probucol: pharmacology and clinical application. Clin. Pharmacol. 30:1990;3-9.
7. Kuzuya M., Kuzuya F. Probucol as an antioxidant and antiatherogenic drug. Free Radic. Biol. Med. 14:1993;67-77.
8. 2 cholesterolemia with abnormal cholesteryl ester transfer. Am. J. Cardiol. 62:1988;66-72.
9. Rader D.J., Castro G., Zech L.A., Fruchart J.C., Brewer H.B. Jr. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles Lp(AI) and Lp(AI-AII). J. Lipid Res. 32:1991;1849-1859.
10. Ohta T., Nakamura R., Ikeda Y., Shinohara M., Miyazaki A., Horiuchi S., Matsude I. Differential effect of subspecies of lipoprotein containing apolipoprotein A-I on cholesterol efflux from cholesterol-loaded macrophages: functional correlation with lecithin cholesterol acyltransferase. Biochim. Biophys. Acta. 1165:1992;119-128.
11. Puchois P., Kandoussi A., Fievet P., Fournier J.L., Bertrand M., Koren M., Fruchart J.C. Apolipoprotein AI containing lipoproteins in coronary artery disease. Atherosclerosis. 68:1987;35-40.
12. Fielding C.J., Fielding P.E. Evidence for a lipoprotein carrier in human plasma catalyzing cholesterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyl transferase. Proc. Natl. Acad. Sci. USA. 77:1981;3911-3914.
13. Duverger N., Ghalim N., Théret N., Fruchart J.C., Gastro G. Lipoproteins containing apolipoprotein AIV: composition and relation to cholesterol esterification. Biochim. Biophys. Acta. 1211:1994;23-28.
14. Sing C.F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37:1985;268-285.
15. Menzel H.J., Kovary P.M., Assman G. Apo AIV polymorphism in man. Hum. Genet. 62:1982;349-352.
16. Ghalim N., Adlouni A., Saïle R., Parra H.J., Benslimane A., Bard J.M., Fruchart J.C. Apolipoprotein AIV of human interstitial fluid is associated to apo AI-containing lipoprotein particles but not to apo AII-containing particles. Int. J. Clin. Lab. Res. 26:1996;224-228.
17. 2. Clin. Chem. 29:1983;2026-2030.
18. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-270.
19. Fruchart J.C., Fievet C., Puchois P. Apolipoproteins. Bergneyer H.U. Methods of Enzymatic Analysis. III:1985;126-135 Academic Press, New York.
20. Parra H.J., Mezdour H., Ghalim N., Bard J.M., Fruchart J.C. Differential electroimmunoassay of human Lp AI lipoprotein particles on ready-to-use plates. Clin. Chem. 36:(8):1990;1431-1435.
21. Koren E., Puchois P., Alaupovic P., Fesmire F.M., Kandoussi A., Fruchart J.C. Quantitative determination of two different types of apo AI-containing lipoprotein particles in human plasma by enzyme-linked differential antibody immunosorbent assay. Clin. Chem. 33:1987;38-43.
22. Chen C., Albers J.J. Characterization of proteoliposomes containing apolipoprotein AI: a new substrate of the measurement of lecithin:cholesterol acyltransferase activity. J. Lipid Res. 23:1982;680-691.
23. Albers J.J., Tollefson J.H., Chen C.H., Steinmetz A. Isolation and characterization of human plasma lipid transfer proteins. Arteriosclerosis. 4:1984;49-58.
24. Helve E., Tikkanen M.J. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Atherosclerosis. 72:1988;189-197.
25. 3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia. Artery. 20:(1):1993;1-18.
26. Dujovne C.A., Harris W.S., Grrond L.L.C., Fan J., Muzio F. Comparison of effects of Probucol versus vitamin E on ex-vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia. Am. J. Cadiol. 74:1994;38-42.
27. Naruszewicz M., Selinger E., Dufour R., Davignon J. Probucol protects lipoprotein (a) against oxidant modification. Metabolism. 41:1992;1225-1228.
28. McPherson R., Hogue M., Milne R.W., Tall A.R., Marcel Y.L. Increase in plasma cholesteryl ester transfer protein during Probucol treatment. Arterioscler. Thromb. 11:1991;476-481.
29. Bagdad J.D., Kaufman D., Ritter M.C., Subbaiah P.V. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. Atherosclerosis. 84:1990;145-154.
30. Franceschini G., Sirtori M., Vaccarino V., Gianfrances-chini G., Rezzonico L., Chiesa G., Sirtori C. Mechanisms of HDL reduction after Probucol: Changes in HDL subfractions and increased cholesteryl ester transfer. Arteriosclerosis. 9:1989;462-469.
31. McLean L., Hagaman K.A. Effect of Probucol on the physical properties of low density lipoproteins oxidized by copper. Biochemistry. 28:1989;321-327.
32. Carew T.E., Schwenke D.C., Stenberg D. Antiatherogenic effect of Probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and show the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:1987;7725-7729.
33. Toikka J.O., Niemi P., Ahotupa M., Niinikoski H., Viikari J.S., Ronnemaa T., Hartiala J.J., Raitaka T. Large-artery elastic properties in young men: relationships to serum lipoproteins and oxidized low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 19:1999;436-441.
34. Bard J.M., Urien S., Fruchart J.C., Tillement J.P. Location of Probucol in lipoproteins interfered from compositional analysis of lipoprotein particles. An in vitro study. J. Pharm. Pharmacol. 46:1994;797-800.
35. Komura T., Takahara K., Sugano M., Fujinishi A., Tasaki H., Nakashima Y., Kuroiwa A. Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol. Eur. J. Drug Metab. Pharmacokinet. 22:1997;201-206.
36. Retterstol K., Stugaard M., Gorbitz C., Ose L. Results of intensive long-term treatment of familial hypercholesterolemia. Am. J. Cardiol. 78:1996;1369-1374.
37. Rinninger F., Pittman M.L. Mechanism of the cholesteryl ester transfer protein mediated uptake of high density lipoprotein cholesterol esters by Hep G2 cells. J. Biol. Chem. 264:1989;6111-6118.
38. Atmeh R.F., Shepherd J., Packard C.J. Subpopulations of apolipoprotein AI in human high-density lipoproteins their metabolic properties and response to drug therapy. Biochim. Biophys. Acta. 751:1983;175-188.
39. Sirtori C., Sirtori M., Calabresi L., Franceschini G. Changes in high-density lipoprotein subfraction distribution and increase cholesterol ester transfer after Probucol. Am. J. Cardiol. 62:1988;73B-76B.
40. Duverger N., Rader D., Duchateau P., Fruchart J.C., Castro G., Brewer H.B. Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma. Biochemistry. 32:1993;12372-12379.
41. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein AI-containing lipoproteins in subjects with coronary artery disease. J. Lipid Res. 32:1991;383-394.
42. Dachet C., Jacotot B., Buxtdorf J.C. The hypolipidemic action of Probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia. Atherosclerosis. 58:1985;261-268.
43. Saku K., Liu R., Ohta T., Jimi S., Matsuda I., Arakawa K. Plasma HDL levels are regulated by the catabolic rate of large particles of lipoprotein containing apo AI. Biochem. Biophys. Res. Comm. 200:1994;557-561.
44. Castro G., Fielding C.J. Early incorporation of cell cholesterol into pre-peta-migration high-density lipoprotein. Biochemistry. 27:1988;25-29.
45. Fielding J.C., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:1995;211-228.
46. Yamamoto A., Matsuzawa Y., Yokoyama S., Funahashi T., Yamamura T., Kishino B.J. Effects of Probucol on xanthoma regression in familial hypercholesterolemia. Am. J. Cardiol. 57:1986;29H.
47. Goldberg R.B., Mendez A. Probucol enhances cholesterol efflux from cultured human skin fibroblasts. Am. J. Cardiol. 62:1988;57B-59B.